Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
NASDAQ:EVAX
Price:
3.22
USD
-5.29%
Market Closed
Market Cap:
$20.4m
Evaxion Biotech A/S
Other Items
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Evaxion Biotech A/S
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Other Items
-$3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Other Items
-kr5.6B
|
CAGR 3-Years
-153%
|
CAGR 5-Years
-78%
|
CAGR 10-Years
-60%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Items
-kr2.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-66%
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Other Items
$11.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Items
-kr48.5m
|
CAGR 3-Years
56%
|
CAGR 5-Years
56%
|
CAGR 10-Years
23%
|
|
No Stocks Found
Evaxion Biotech A/S
Glance View
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
EVAX
Intrinsic Value
6.72
USD
Undervaluation 52%
See Also
What is Evaxion Biotech A/S's Other Items?
Other Items
-3k
USD
-3k
USD
Based on the financial report for Dec 31, 2024, Evaxion Biotech A/S's Other Items amounts to -3k USD.
What is Evaxion Biotech A/S's Other Items growth rate?
Other Items CAGR 1Y
50%
50%
Over the last year, the Other Items growth was 50%.
